CPRX Catalyst Pharmaceuticals Inc
Price (delayed)
$23.12
Market cap
$2.81B
P/E Ratio
16.75
Dividend/share
N/A
EPS
$1.38
Enterprise value
$2.29B
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK
Highlights
Catalyst Pharmaceuticals's net income has surged by 130% YoY and by 15% QoQ
The EPS has soared by 106% year-on-year and by 10% since the previous quarter
The stock's P/E is 20% less than its last 4 quarters average of 21.0 but 6% more than its 5-year quarterly average of 15.8
Key stats
What are the main financial stats of CPRX
Market
Valuations
Earnings
Shares outstanding
121.45M
Market cap
$2.81B
Enterprise value
$2.29B
Price to earnings (P/E)
16.75
Price to book (P/B)
3.79
Price to sales (P/S)
5.57
EV/EBIT
10.6
EV/EBITDA
9.02
EV/Sales
4.66
Revenue
$491.73M
Gross profit
$422.89M
Operating income
$195.12M
Net income
$163.89M
EBIT
$216.26M
EBITDA
$254.32M
Free cash flow
$239.25M
Per share
Balance sheet
Liquidity
EPS
$1.38
EPS diluted
$1.31
Free cash flow per share
$2.02
Book value per share
$6.1
Revenue per share
$4.15
TBVPS
$5.86
Total assets
$851.41M
Total liabilities
$123.78M
Debt
$2.79M
Equity
$727.63M
Working capital
$502.93M
Debt to equity
0
Current ratio
5.17
Quick ratio
4.83
Net debt/EBITDA
-2.02
Margins
Efficiency
Dividend
EBITDA margin
51.7%
Gross margin
86%
Net margin
33.3%
Operating margin
39.7%
Return on assets
22%
Return on equity
25.6%
Return on invested capital
330.8%
Return on capital employed
29.6%
Return on sales
44%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CPRX stock price
How has the Catalyst Pharmaceuticals stock price performed over time
Intraday
2.3%
1 week
4.19%
1 month
-4.58%
1 year
56.96%
YTD
10.78%
QTD
-4.66%
Financial performance
How have Catalyst Pharmaceuticals's revenue and profit performed over time
Revenue
$491.73M
Gross profit
$422.89M
Operating income
$195.12M
Net income
$163.89M
Gross margin
86%
Net margin
33.3%
Catalyst Pharmaceuticals's net income has surged by 130% YoY and by 15% QoQ
The company's operating income has surged by 125% YoY and by 12% QoQ
Catalyst Pharmaceuticals's net margin has surged by 86% YoY and by 7% QoQ
The operating margin has soared by 82% YoY and by 5% QoQ
Growth
What is Catalyst Pharmaceuticals's growth rate over time
Valuation
What is Catalyst Pharmaceuticals stock price valuation
P/E
16.75
P/B
3.79
P/S
5.57
EV/EBIT
10.6
EV/EBITDA
9.02
EV/Sales
4.66
The EPS has soared by 106% year-on-year and by 10% since the previous quarter
The stock's P/E is 20% less than its last 4 quarters average of 21.0 but 6% more than its 5-year quarterly average of 15.8
Catalyst Pharmaceuticals's equity has surged by 88% YoY and by 10% QoQ
The stock's price to book (P/B) is 15% more than its last 4 quarters average of 3.3 and 5% more than its 5-year quarterly average of 3.6
The revenue rose by 23% YoY and by 7% QoQ
The price to sales (P/S) is 19% higher than the last 4 quarters average of 4.7 and 16% higher than the 5-year quarterly average of 4.8
Efficiency
How efficient is Catalyst Pharmaceuticals business performance
The ROS has soared by 86% year-on-year and by 7% since the previous quarter
The ROIC has soared by 73% year-on-year and by 17% since the previous quarter
CPRX's return on assets is up by 33% year-on-year
The ROE has increased by 29% YoY
Dividends
What is CPRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CPRX.
Financial health
How did Catalyst Pharmaceuticals financials performed over time
Catalyst Pharmaceuticals's quick ratio has surged by 92% YoY
The total assets has soared by 81% year-on-year and by 10% since the previous quarter
Catalyst Pharmaceuticals's debt is 100% lower than its equity
CPRX's debt to equity has dropped by 100% year-on-year
Catalyst Pharmaceuticals's equity has surged by 88% YoY and by 10% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.